Genetics of epilepsy in clinical practice

Epilepsy Currents

Volumn 15, Issue 4, 2015, Pages 192-196

  Berkovic, Samuel F ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; EPILEPSY; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; HUMAN; INHERITANCE; KCNQ2 GENE; LOSS OF FUNCTION MUTATION; PHENOTYPE; REVIEW; SCN1A GENE; SCN2A GENE; SCN8A GENE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SLC2A1 GENE;

EID: 84942867290     PISSN: 15357597     EISSN: 15357511     Source Type: Journal    
DOI: 10.5698/1535-7511-15.4.192     Document Type: Review

References (47)

1. Thomas RH, Berkovic SF. The hidden genetics of epilepsy-A clinically important new paradigm. Nat Rev Neurol 2014;10:283-292.
2. Poduri A, Evrony GD, Cai X, Walsh CA. Somatic mutation, genomic variation, and neurological disease. Science 2013;341:1237758. doi:10.1126/science1237758.
3. Noebels J. Pathway-driven discovery of epilepsy genes. Nat Neurosci 2015;18:344-350.
4. Mefford HC. Clinical genetic testing in epilepsy. Epilepsy Curr 2015;15:206-210.
5. Plouin P, Neubauer BA. Benign familial and non-familial neonatal seizures. In: Epileptic Syndromes in Infancy, Childhood and Adolescence. (Bureau M, Genton P, Dravet C, Delgado-Escueta A, Tassinari CA, Thomas P, Wolf P, eds.) Montrouge, France: John Libbey Eurotext, 2012:77-88.
6. Scheffer IE, Bhatia KP, Lopes-Cendes I, Fish DR, Marsden CD, Andermann E, Andermann F, Desbiens R, Keene D, Cendes F, Manson JI, Constantinou JEC, McIntosh A, Berkovic SF. Autosomal dominant nocturnal frontal lobe epilepsy: A distinctive clinical disorder. Brain 1995;118:61-73.
7. Shoubridge C, Fullston T, Gécz J. ARX spectrum disorders: Making inroads into the molecular pathology. Hum Mutat 2010;31:889-900.
8. Guerrini R, Dobyns WB. Malformations of cortical development: Clinical features and genetic causes. Lancet Neurol 2014;13:710-726.
9. Hynes K, Tarpey P, Dibbens LM, Bayly MA, Berkovic SF, Smith R, Al Raisi Z, Turner SJ, Brown NJ, Desai TD, Haan E, Turner G, Christodoulou J, Leonard H, Gill D, Stratton MR, Gecz J, Scheffer IE. Epilepsy and mental retardation limited to females with PCDH19 mutations can present de novo or in single generation families. J Med Genet 2010;47:211-216.
10. Depienne C, LeGuern E. PCDH19-related infantile epileptic encephalopathy: An unusual X-linked inheritance disorder. Hum Mutat 2012;33:627-634.
11. Helbig I, Scheffer IE, Mulley JC, Berkovic SF. Navigating the channels and beyond: Unravelling the genetics of the epilepsies. Lancet Neurol 2008;7:231-245.
12. Epi4K Consortium. Epi4K: Gene discovery in 4, 000 genomes. Epilepsia 2012;53:1457-1467.
13. Peljto AL, Barker-Cummings C, Vasoli VM, Leibson CL, Hauser WA, Buchhalter JR, Ottman R. Familial risk of epilepsy: A population-based study. Brain 2014;137:795-805.
14. Arsov T, Mullen SA, Rogers S, Phillips AM, Lawrence KM, Damiano JA, Goldberg-Stern H, Afawi Z, Kivity S, Trager C, Petrou S, Berkovic SF, Scheffer IE. GLUT1-deficiency in the idiopathic generalised epilepsies. Ann Neurol 2012;72:807-815.
15. Ottman R, Winawer MR, Kalachikov S, Barker-Cummings C, Gilliam TC, Pedley TA, Hauser WA. LGI1 mutations in autosomal dominant partial epilepsy with auditory features. Neurology 2004;62:1120-1126.
16. Dibbens LM, de Vries B, Donatello S, Heron SE, Hodgson BL, Chintawar S, Crompton DE, Hughes JN, Bellows ST, Klein KM, Callenbach PM, Corbett MA, Gardner AE, Kivity S, Iona X, Regan BM, Weller CM, Crimmins D, O'Brien TJ, Guerrero-López R, Mulley JC, Dubeau F, Licchetta L, Bisulli F, Cossette P, Thomas PQ, Gecz J, Serratosa J, Brouwer OF, Andermann F, Andermann E, van den Maagdenberg AM, Pandolfo M, Berkovic SF, Scheffer IE. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 2013;45:546-551.
17. Picard F, Makrythanasis P, Navarro V, Ishida S, de Bellescize J, Ville D, Weckhuysen S, Fosselle E, Suls A, De Jonghe P, Vasselon Raina M, Lesca G, Depienne C, An-Gourfinkel I, Vlaicu M, Baulac M, Mundwiller E, Couarch P, Combi R, Ferini-Strambi L, Gambardella A, Antonarakis SE, Leguern E, Steinlein O, Baulac S. DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology 2014;82:2101-2106.
18. Scheffer IE, Heron SE, Regan BM, Mandelstam S, Crompton DE, Hodgson BL, Licchetta L, Provini F, Bisulli F, Vadlamudi L, Gecz J, Connelly A, Tinuper P, Ricos MG, Berkovic SF, Dibbens LM. Mutations in mTOR regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol 2014;75:782-787.
19. Baulac S, Ishida S, Marsan E, Miquel C, Biraben A, Nguyen DK, Nordli D, Cossette P, Nguyen S, Lambrecq V, Vlaicu M, Daniau M, Bielle F, Andermann E, Andermann F, Leguern E, Chassoux F, Picard F. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol 2015;77:675-683.
20. D'Gama AM, Geng Y, Couto JA, Martin B, Boyle EA, LaCoursiere CM, Hossain A, Hatem NE, Barry BJ, Kwiatkowski DJ, Vinters HV, Barkovich AJ, Shendure J, Mathern GW, Walsh CA, Poduri A. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann Neurol 2015;77:720-725.
21. Delgado-Escueta AV, Bourgeois BF. Debate: Does genetic information in humans help us treat patients? PRO-genetic information in humans helps us treat patients. CON-genetic information does not help at all. Epilepsia 2008;49(suppl 9):13-24.
22. Berkovic SF, Harkin L, McMahon JM, Pelekanos JT, Zuberi SM, Wirrell EC, Gill DS, Iona X, Mulley JC, Scheffer IE. De novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: A retrospective study. Lancet Neurol 2006;5:488-492.
23. Vears DF, Dunn KL, Wake SA, Scheffer IE. "It's good to know": Experiences of gene identification and result disclosure in familial epilepsies. Epilepsy Res 2015;112:64-71.
24. Walters J, Wells-Kilpatrick K, Pandeleos T. My epilepsy story-PCDH19 alliance. Epilepsia 2014;55:968-969.
25. Nakagawa JA. My epilepsy story-The Tuberous Sclerosis Alliance. Epilepsia 2014;55:494-495.
26. Maxwell A. My epilepsy story-Muir Maxwell Trust. Epilepsia 2014;55:1690-1692.
27. Ottman R, Hirose S, Jain S, Lerche H, Lopes-Cendes I, Noebels JL, Serratosa J, Zara F, Scheffer IE. Genetic testing in the epilepsies-Report of the ILAE Genetics Commission. Epilepsia 2010;51:655-670.
28. Poduri A, Sheidley BR, Shostak S, Ottman R. Genetic testing in the epilepsies-Developments and dilemmas. Nat Rev Neurol 2014;10:293-299.
29. De Wolf V, Brison N, Devriendt K, Peeters H. Genetic counseling for susceptibility loci and neurodevelopmental disorders: The del15q11.2 as an example. Am J Med Genet A 2013;161A:2846-2854.
30. Shostak S, Ottman R. Ethical, legal, and social dimensions of epilepsy genetics. Epilepsia 2006;47:1595-1602.
31. Okeke JO, Tangel VE, Sorge ST, Hesdorffer DC, Winawer MR, Goldsmith J, Phelan JC, Chung WK, Shostak S, Ottman R. Genetic testing preferences in families containing multiple individuals with epilepsy. Epilepsia 2014;55:1705-1713.
32. Brunklaus A, Dorris L, Ellis R, Reavey E, Lee E, Forbes G, Appleton R, Cross JH, Ferrie C, Hughes I, Jollands A, King MD, Livingston J, Lynch B, Philip S, Scheffer IE, Williams R, Zuberi SM. The clinical utility of an SCN1A genetic diagnosis in infantile-onset epilepsy. Dev Med Child Neurol 2013;55:154-161.
33. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia 2011;52(suppl 2):72-75.
34. Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 2012;135:2329-2336.
35. Hirose S, Scheffer IE, Marini C, De Jonghe P, Andermann E, Goldman AM, Kauffman M, Tan NC, Lowenstein DH, Sisodiya SM, Ottman R, Berkovic SF; Genetics Commission of the International League Against Epilepsy. SCN1A testing for epilepsy: Application in clinical practice. Epilepsia 2013;54:946-952.
36. Catarino CB, Liu JY, Liagkouras I, Gibbons VS, Labrum RW, Ellis R, Woodward C, Davis MB, Smith SJ, Cross JH, Appleton RE, Yendle SC, McMahon JM, Bellows ST, Jacques TS, Zuberi SM, Koepp MJ, Martinian L, Scheffer IE, Thom M, Sisodiya SM. Dravet syndrome as epileptic encephalopathy: Evidence from long-term course and neuropathology. Brain 2011;134:2982-3010.
37. Kassaï B, Chiron C, Augier S, Cucherat M, Rey E, Gueyffier F, Guerrini R, Vincent J, Dulac O, Pons G. Severe myoclonic epilepsy in infancy: A systematic review and a meta-analysis of individual patient data. Epilepsia 2008;49:343-348.
38. Nakamura K, Kato M, Osaka H, Yamashita S, Nakagawa E, Haginoya K, Tohyama J, Okuda M, Wada T, Shimakawa S, Imai K, Takeshita S, Ishiwata H, Lev D, Lerman-Sagie T, Cervantes-Barragán DE, Villarroel CE, Ohfu M, Writzl K, Gnidovec Strazisar B, Hirabayashi S, Chitayat D, Myles Reid D, Nishiyama K, Kodera H, Nakashima M, Tsurusaki Y, Miyake N, Hayasaka K, Matsumoto N, Saitsu H. Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology 2013;81:992-998.
39. Larsen J, Carvill GL, Gardella E, Kluger G, Schmiedel G, Barisic N, Depienne C, Brilstra E, Mang Y, Nielsen JE, Kirkpatrick M, Goudie D, Goldman R, Jähn JA, Jepsen B, Gill D, Döcker M, Biskup S, McMahon JM, Koeleman B, Harris M, Braun K, de Kovel CG, Marini C, Specchio N, Djémié T, Weckhuysen S, Tommerup N, Troncoso M, Troncoso L, Bevot A, Wolff M, Hjalgrim H, Guerrini R, Scheffer IE, Mefford HC, Møller RS; EuroEPINOMICS RES Consortium CRP. The phenotypic spectrum of SCN8A encephalopathy. Neurology 2015;84:480-489.
40. Pisano T, Numis AL, Heavin SB, Weckhuysen S, Angriman M, Suls A, Podesta B, Thibert RL, Shapiro KA, Guerrini R, Scheffer IE, Marini C, Cilio MR. Early and effective treatment of KCNQ2 encephalopathy. Epilepsia 2015;56:685-691. doi:10.1111/epi.
41. Scheffer IE. GLUT1 deficiency: A glut of epilepsy phenotypes. Neurology 2012;78:524-525.
42. Pearson TS, Akman C, Hinton VJ, Engelstad K, De Vivo DC. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep 2013;13:342. doi:10.1007/s11910-013-0342-7.
43. Stockler S, Plecko B, Gospe SM Jr, Coulter-Mackie M, Connolly M, van Karnebeek C, Mercimek-Mahmutoglu S, Hartmann H, Scharer G, Struijs E, Tein I, Jakobs C, Clayton P, Van Hove JL. Pyridoxine dependent epilepsy and antiquitin deficiency: Clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011;104:48-60.
44. Mills PB, Camuzeaux SS, Footitt EJ, Mills KA, Gissen P, Fisher L, Das KB, Varadkar SM, Zuberi S, McWilliam R, Stödberg T, Plecko B, Baumgartner MR, Maier O, Calvert S, Riney K, Wolf NI, Livingston JH, Bala P, Morel CF, Feillet F, Raimondi F, Del Giudice E, Chong WK, Pitt M, Clayton PT. Epilepsy due to PNPO mutations: Genotype, environment and treatment affect presentation and outcome. Brain 2014;137:1350-1360.
45. Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, Trager C, Reid CA, Venkat A, Younkin DP, Dlugos DJ, Petrovski S, Goldstein DB, Dibbens LM, Scheffer IE, Berkovic SF, Petrou S. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 2014;75:581-590.
46. Bearden D, Strong A, Ehnot J, DiGiovine M, Dlugos D, Goldberg EM. Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 2014;76:457-461.
47. Pierson TM, Yuan H, Marsh ED, Fuentes-Fajardo K, Adams DR, Markello T, Golas G, Simeonov DR, Holloman C, Tankovic A, Karamchandani MM, Schreiber JM, Mullikin JC; PhD for the NISC Comparative Sequencing Program, Tifft CJ, Toro C, Boerkoel CF, Traynelis SF, Gahl WA. GRIN2A mutation and early-onset epileptic encephalopathy: Personalized therapy with memantine. Ann Clin Transl Neurol 2014;1:190-198.